Published in Gynecol Oncol on February 01, 2002
Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol (2008) 3.94
Cancer of the endometrium: current aspects of diagnostics and treatment. World J Surg Oncol (2004) 0.87
Lymphadenectomy for endometrial cancer: is paraaortic lymphadenectomy necessary? Int J Clin Oncol (2007) 0.87
Adjuvant brachytherapy for Stage IB Grade 2 endometrial carcinoma: Multivariate analysis of a single institution experience. Indian J Med Paediatr Oncol (2016) 0.75
Is adjuvant radiotherapy necessary for FIGO stage 1a grade 2 endometrial endometrioid adenocarcinoma? J Turk Ger Gynecol Assoc (2015) 0.75
Permanent interstitial re-irradiation with Au-198 seeds in patients with post-radiation locally recurrent uterine carcinoma. J Radiat Res (2012) 0.75
Adjuvant therapy in early-stage endometrial cancer: a systematic review of the evidence, guidelines, and clinical practice in the U.S. Oncologist (2014) 0.75
No regrets, no illusions. Gynecol Oncol (2002) 0.75
Predictors of limph node metastasis in endometrial cancer. Clujul Med (2013) 0.75
Controversies in the adjuvant therapy of endometrial cancer. ISRN Obstet Gynecol (2011) 0.75
Liver recurrence in early endometrial cancer with focal myometrial invasion. Obstet Gynecol Sci (2013) 0.75
Factors associated with survival after relapse in patients with low-risk endometrial cancer treated with surgery alone. J Gynecol Oncol (2017) 0.75
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol (2013) 5.40
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis (2013) 3.06
American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin (2007) 2.81
Cervical cancer prevention: new tools and old barriers. Cancer (2010) 2.68
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol (2011) 2.62
Potential savings from greater use of $4 generic drugs. Arch Intern Med (2011) 2.48
SIVcpz in wild chimpanzees. Science (2002) 2.45
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 2.24
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res (2011) 2.03
Low yield of residual vulvar carcinoma and dysplasia upon re-excision for close or positive margins. Gynecol Oncol (2013) 2.01
Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer (2009) 1.98
Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer (2006) 1.92
Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res (2002) 1.89
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer. Obstet Gynecol (2006) 1.77
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res (2002) 1.74
The Deep South Network for cancer control. Building a community infrastructure to reduce cancer health disparities. Cancer (2006) 1.71
Haploinsufficiency of SGO1 results in deregulated centrosome dynamics, enhanced chromosomal instability and colon tumorigenesis. Cell Cycle (2012) 1.71
Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer (2004) 1.70
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst (2002) 1.61
Planning and implementation of a participatory evaluation strategy: a viable approach in the evaluation of community-based participatory programs addressing cancer disparities. Eval Program Plann (2009) 1.61
An examination of acceptability of HPV vaccination among African American women and Latina immigrants. J Womens Health (Larchmt) (2007) 1.60
Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix. Gynecol Oncol (2012) 1.58
Lynch syndrome in women less than 50 years of age with endometrial cancer. Obstet Gynecol (2008) 1.54
A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol (2007) 1.53
Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinoma. Obstet Gynecol (2007) 1.49
Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high-risk factors based on long-term follow-up. World J Surg (2005) 1.47
Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. Obstet Gynecol (2014) 1.46
Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy. Gynecol Oncol (2005) 1.45
A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res (2004) 1.44
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther (2003) 1.43
Complete genome sequence of Aeromonas veronii strain B565. J Bacteriol (2011) 1.43
The effect of the US Medicare Part D coverage gaps on medication use among patients with depression and heart failure. J Ment Health Policy Econ (2012) 1.42
The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: a patient care evaluation study from the American College of Surgeons National Cancer Data Base. Gynecol Oncol (2005) 1.41
Knowledge, beliefs, and practices concerning seat belt use during pregnancy. J Trauma (2004) 1.41
Trends in hospital volume and patterns of referral for women with gynecologic cancers: adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol (2013) 1.41
Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat (2007) 1.41
Pelvic umbrella pack for refractory obstetric hemorrhage secondary to posterior uterine rupture. Obstet Gynecol (2002) 1.41
Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol (2003) 1.40
Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients. Oncologist (2006) 1.40
Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment. Gynecol Oncol (2002) 1.38
Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer (2003) 1.38
Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol (2007) 1.37
The vast majority of Medicare Part D beneficiaries still don't choose the cheapest plans that meet their medication needs. Health Aff (Millwood) (2012) 1.36
New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol (2003) 1.34
An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol (2009) 1.29
Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res (2008) 1.29
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther (2002) 1.28
Comparison of predictive values of two diagnostic tests from the same sample of subjects using weighted least squares. Stat Med (2006) 1.28
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27
Cervical cancer. J Natl Compr Canc Netw (2013) 1.24
Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol (2007) 1.23
Comprehensive surgical staging for endometrial cancer in obese patients: comparing robotics and laparotomy. Obstet Gynecol (2009) 1.22
A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res (2010) 1.21
Postmenopausal uterine inversion associated with endometrial polyps. Obstet Gynecol (2003) 1.19
Folate is associated with the natural history of high-risk human papillomaviruses. Cancer Res (2004) 1.18
Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. Prev Med (2011) 1.18
Optical detection of high-grade cervical intraepithelial neoplasia in vivo: results of a 604-patient study. Am J Obstet Gynecol (2004) 1.17
Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol (2007) 1.16
Epithelial ovarian cancer. J Natl Compr Canc Netw (2011) 1.16
Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol (2011) 1.15
Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res (2002) 1.15
A population-based validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2005) 1.14
Treatment preferences in recurrent ovarian cancer. Gynecol Oncol (2002) 1.14
A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res (2002) 1.14
Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res (2003) 1.14
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol (2009) 1.14
Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. J Clin Oncol (2009) 1.14
Smoothened antagonists reverse taxane resistance in ovarian cancer. Mol Cancer Ther (2012) 1.13
Ovarian cancer, version 2.2013. J Natl Compr Canc Netw (2013) 1.13
Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther (2004) 1.12
Impact of Medicare Part D on antidepressant treatment, medication choice, and adherence among older adults with depression. Am J Geriatr Psychiatry (2011) 1.11